Chronic Coronary Syndrome Clinical Trial
Official title:
Efficacy and Safety of Yangxinshi Tablet in Improving Exercise Tolerance in Patients With Chronic Coronary Syndrome(Qi Deficiency and Blood Stasis Syndrome):A Randomized, Double-blind,Placebo-parallel-controlled,Multicenter Clinical Study
This study adopted a randomized, double-blind, placebo-controlled, multicenter clinical design and compared the effects of Yangxinshi tablet and placebo on exercise tolerance in patients with chronic coronary syndrome (CCS).
The aim of the research is to find out if the addition of Yangxinshi tablets on the basis of conventional treatment can improve exercise tolerance of patients with chronic coronary syndrome (CCS), improve quality of life and mental health. A total of 120 qualified CCS patients were randomly divided into two groups. In addition to conventional treatment, the experimental group was given Yangxinshi tablets (3 tablets/time and 3 times/day), and the control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day). The treatment period was 24 weeks. The primary endpoints were metabolic equivalents (METs), and peak oxygen uptake measured by cardiopulmonary exercise testing after 24 weeks of treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06185530 -
SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints
|
N/A | |
Recruiting |
NCT05117866 -
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
|
N/A | |
Recruiting |
NCT05727982 -
Identification of Molecular Mechanisms of Coronary Instability in Homogeneous Subsets of Patients With Acute Coronary Syndromes for the Implementation of Precision Medicine
|
||
Completed |
NCT06464276 -
Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
|
||
Recruiting |
NCT03936504 -
Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation Model
|
N/A | |
Recruiting |
NCT05875311 -
Telemonitoring System for Improving Continuity of Care in Patients With Chronic Coronary Syndrome (TELSINCORC)
|
N/A | |
Recruiting |
NCT05865600 -
Perfusion Estimation For Optimal Treatment Strategy in Chronic Coronary Syndrome
|
N/A | |
Recruiting |
NCT06337461 -
Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction Based on cOronary Artery Stenosis and Atherosclerotic Plaque Burden Assessment by Computed Tomography
|
||
Recruiting |
NCT05640752 -
Optimal Evaluation to Reduce Imaging Testing
|
N/A | |
Recruiting |
NCT05635994 -
Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO)
|
||
Recruiting |
NCT05583786 -
Intracoronary ECG ST-segment Shift Remission Time During Reactive Coronary Hyperemia
|
||
Completed |
NCT05592535 -
Outcomes With Fractional Flow Reserve in Chronic Coronary Syndrome
|
||
Recruiting |
NCT06255678 -
Angio-based Final Functional Effect of PCI
|
||
Recruiting |
NCT06275399 -
Comprehensive Assessment of Morphometric, Functional, Biomechanical and Biological Interactions Between Atherosclerotic Plaque and Platelets Within the Stenosed Coronary Artery
|
||
Not yet recruiting |
NCT06186336 -
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
|
||
Withdrawn |
NCT04738344 -
Very Long Versus Overlapping Stents in Long Coronary Lesions
|
N/A | |
Active, not recruiting |
NCT04135989 -
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES
|
Phase 4 | |
Recruiting |
NCT05674630 -
Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons
|
Phase 4 | |
Recruiting |
NCT06171061 -
Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome
|
Phase 4 | |
Recruiting |
NCT05379608 -
Intermittent Hypoxic-hyperoxic Training in Patients With Cardiovascular Pathology After COVID-19 Infection.
|
N/A |